29 May 2019
Wenyeli Ramirez

iVascular launches innoVasc, a new open innovation program that tackles the current and future challenges of vascular therapies.

iVascular is pleased to announce its open innovation initiative innoVasc, in order to promote innovation and transform vascular therapies, to provide the market with advanced treatments for the diseases of the cardiovascular system. The contest is looking for proposals, approaches, solutions and ideas for vascular therapies from the following areas of interest: Medical devices for […]

read more
Share this
28 May 2019
Wenyeli Ramirez

New study in ISR with essential DCB presented at EuroPCR 2019.

ESSENTIAL ISR is a prospective, multicenter and single arm study that sought to assess the efficacy of essential paclitaxel-eluting balloon, in the setting of ISR. The primary end-point was OCT derived in-segment maximal area stenosis. Secondary endpoints included QCA-derived in-segment late lumen loss (LLL) at 6 months and target lesion failure (TLF) rate at 6, […]

read more
Share this
23 May 2019
Wenyeli Ramirez

EFFPAC RCT 24-month has revealed in EuroPCR 2019 that luminor DCB demonstrate a non-increase of risk of death at 24-month follow-up

Barcelona, May 23st, 2019 – EFFPAC RCT 24-month outstanding safety and efficacy results have been presented for the first time at EuroPCR 2019. The 24-month results from the EFFPAC trial have been presented by Prof Ulf Teichgräber at the Hot line/ Late breaking peripheral trials session. EFFPAC is a physician initiated multicenter, randomized and controlled […]

read more
Share this
22 May 2019
Wenyeli Ramirez

Latest generation DES: ANGIOLITE trial 24-month outcomes revealed at EuroPCR 2019 the non-inferiority of angiolite vs the gold standard EES

Barcelona, May 22nd, 2019 – ANGIOLITE trial 24-month data has been presented for the first time at EuroPCR 2019 by Dr Perez de Prado. These outcomes show high efficacy and safety regarding angiolite, one of the best new generation DES. ANGIOLITE trial is a prospective, randomized, multicenter and controlled trial designed to test the non-inferiority […]

read more
Share this
08 May 2019
Wenyeli Ramirez

Are DCB safe? Not all DCB are the same.

EFFPAC 2-year safety and efficacy outcomes presented at EuroPcr. EFFPAC trial 24-month safety results will be presented for the first time by Prof Ulf Teichgräber at EuroPcr 2019 in the Hot line/ Late breaking trials session, taking place in room 342 A, level 3 from 13:45 to 15:15. The main objective of EFFPAC RCT was to assess […]

read more
Share this
02 Apr 2019
Wenyeli Ramirez

iVascular launches iVascular Grant program

Barcelona, April 1th, 2019. iVascular specialized company in developing high quality vascular devices, is committed with the expansion of knowledge of young specialists in international reference centers through training grants. Therefore, the company has launched the iVascular Grant program.   The program has been developed in association with the Endovascular Foundation, that in accordance with […]

read more
Share this
12 Feb 2019
Marta Enrich

Navitian, iVascular´s new coronary microcatheter receives the CE mark approval.

Barcelona, February 12th, 2019. – Navitian, iVascular´s new coronary microcatheter receives the CE mark approval. iVascular is pleased to announce the release of Navitian, it’s a new Coronary Microcatheter, which has obtained the CE mark approval to: Facilitate, guide and support a guidewire while accessing to the coronary system, the exchange of guidewire and injection […]

read more
Share this
14 Nov 2018
Marta Enrich

iVascular completes the enrollment of patients in T.I.N.T.I.N. study

Barcelona, November 14th of 2018.- iVascular S.L.U. has announced the completion of enrollment of patients in its T.I.N.T.I.N. (Treatment with the LumINor DCB and The IvolutioN self-expanding stent) study. The effectiveness of drug coated balloons (DCB) to inhibit restenosis in symptomatic superficial femoral artery (SFA) lesions, has been proven in many studies. However, the longer […]

read more
Share this
19 Oct 2018
Marta Enrich

iVascular acquires 10% of the shares of the American company NaviGate Cardiac Structures, Inc. for 10 million dollars.

Sant Vicenç dels Horts (Barcelona), October 18th of 2018.- Today, the collaboration agreement between iVascular and NaviGate Cardiac Structures, Inc (NCSI) has been formalized, under which iVascular acquires 10% of shares of NCSI for 10 million dollars. With this purchase, iVascular becomes part of the Board of Directors of the American company. The mentioned agreement […]

read more
Share this
04 Oct 2018
Marta Enrich

iVascular reveals 24 months outcomes of Anchor trial and presents outcomes of two major RCT at TCT 2018.

San Diego, September 24th, 2018 – iVascular reveals 24 months outcomes of Anchor trial and presents outcomes of two major RCT at TCT 2018. iVascular reveals 24 months outcomes of ANCHOR Trial, evaluating the safety and efficacy of Angiolite DES, at TCT 2018. The presentation was made by Dr. Rishi Puri, one of the PI […]

read more
Share this
04 Oct 2018
Marta Enrich

iVascular demonstrates benefits of leading products at CIRSE 2018

Lisbon, September 23rd, 2018. iVascular demonstrates benefits of leading products at CIRSE 20. 18The 12-month results from the full clinical cohort of the EFFPAC randomized controlled trial (RCT), were presented by Prof.Ulf Teichgräber (Jena University, Germany) at CIRSE 2018. Main objective of EFFPAC RCT was to assess the effectiveness of Luminor drug coated balloon (DCB) vs. […]

read more
Share this
28 May 2018
Marta Enrich

ANGIOLITE Trial 12-month results revealed at Euro PCR 2018

Paris, May 24th, 2018 – ANGIOLITE Trial 12-month results revealed at Euro PCR 2018 ANGIOLITE Trial 12-month results were presented for the first time at Euro PCR by Dr. J. Moreu Burgos at the “Clinical outcomes with new DES” session. The randomized prospective multicentric controlled trial enrolled 223 patients and had the objective of demonstrating […]

read more
Share this

© 2018 iVascular SLU. All rights reserved. Legal Notice | Terms of use

We use cookies to guarantee the best experience in your navigation. If you continue browsing consider to accept the use of cookies. More information

ACEPTAR
Aviso de cookies